Alzheimer’s Disease Biomarkers Market to Grow with a CAGR of 7.25% through 2028
Rising aging population and increasing
investment in research and development are factors driving the global Alzheimer’s
Disease Biomarkers market in the forecast period 2024-2028
According to TechSci Research report, “Alzheimer’s
Disease Biomarkers Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Alzheimer’s
Disease Biomarkers
Market stood at USD 835.25 Million in 2022 and is anticipated to grow with a
CAGR of 7.25% in the forecast period, 2024-2028. Alzheimer's disease is a
progressive neurodegenerative disorder that affects millions of individuals
worldwide. As the global population ages, the prevalence of Alzheimer's disease
continues to rise, making it one of the most pressing healthcare challenges of
our time. The need for effective diagnostic tools and therapies has led to
significant growth in the Alzheimer's Disease Biomarkers market. One of the
primary drivers of the Alzheimer's Disease Biomarkers market is the aging
population. As people live longer, the incidence of Alzheimer's disease
increases. According to the World Health Organization (WHO), the number of
people aged 60 and older is expected to double by 2050. With age being one of
the most significant risk factors for Alzheimer's disease, the demand for early
and accurate diagnostic biomarkers is on the rise.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Alzheimer’s
Disease Biomarkers Market”
Alzheimer's disease prevalence has been
steadily increasing over the years. The Alzheimer's Association estimates that
more than 6 million Americans have Alzheimer's disease, and this number is
expected to grow as the population ages. This rising prevalence fuels the
demand for biomarkers that can aid in early detection, intervention, and
monitoring of the disease's progression.
The field of Alzheimer's disease
research has seen significant advancements in recent years. Researchers have
made breakthroughs in understanding the underlying pathology of the disease,
leading to the identification of potential biomarkers. These advancements have
driven the development of novel diagnostic tools and therapeutic interventions,
creating a thriving market for Alzheimer's disease biomarkers. Pharmaceutical
companies, academic institutions, and research organizations have shown a
growing interest in Alzheimer's disease research. This has led to increased
investment in research and development, with a specific focus on identifying
and validating biomarkers. As a result, the market has witnessed the emergence
of innovative biomarker candidates that have the potential to revolutionize
Alzheimer's disease diagnosis and treatment.
The Global Alzheimer’s Disease Biomarkers Market is
segmented into type, detection technique, end user, company and region
Based on detection technique, the Immunoassays segment has
emerged as the predominant market leader.
Immunoassays,
particularly enzyme-linked immunosorbent assays (ELISAs), offer high
sensitivity and specificity in detecting Alzheimer's disease biomarkers like
amyloid beta (Aβ) and tau proteins. This accuracy is crucial for early
diagnosis and monitoring. Immunoassay techniques for Alzheimer's disease
biomarkers have well-established protocols, making them reliable and consistent
in clinical settings.
Based on region, North America segment is expected to
grow during the forecast period. North America's robust clinical
trial ecosystem attracts pharmaceutical companies and researchers from around
the world. This ecosystem provides fertile ground for biomarker discovery and
validation, as clinical trials often involve the collection of data and samples
that can be used to identify potential biomarkers. North America has seen significant private and public
investments in Alzheimer's research and biomarker development. Venture capital
firms, philanthropic organizations, and government agencies allocate
substantial funds to support innovative research projects and startups focused
on Alzheimer's biomarkers.
The Asia Pacific region is experiencing rapid market
growth. Strong Alzheimer's disease advocacy organizations in Asia Pacific have
raised public awareness about the disease's devastating effects. These groups
push for increased research funding and support, further driving biomarker
development efforts.
Major companies operating in Global Alzheimer’s
Disease Biomarkers Market are:
- Enzo Life Sciences Inc.
- Thermo Fisher Scientific Inc.
- AnaSpec Inc.
- Merck KGaA
- Cell Signaling Technology Inc.
- Fujirebio Diagnostics Inc
- 23andMe Inc.
- NanoSomiX Inc.
- QIAGEN NV
- Quest Diagnostics
Download
Free Sample Report
Customers can also request for 10% free
customization on this report
“The Global Alzheimer's Disease Biomarkers Market is
poised for substantial growth, driven by factors like the aging population,
rising disease prevalence, advances in medical research, increased investment
in R&D, regulatory support, heightened awareness, and technological
advancements. These market drivers not only create opportunities for the
development of novel biomarkers but also pave the way for early diagnosis,
personalized treatment, and improved outcomes for individuals affected by
Alzheimer's disease.,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Alzheimer’s Disease Biomarkers Market By Type
(CSF Biomarkers, Amyloid Beta, Tau Protein, Genetic Biomarkers, Apolipoprotein
E, Blood Biomarkers, Others), By Detection Technique (Detection Technique,
Immunoassays), By End user (Hospitals & Clinics, Diagnostic Laboratories,
Others), By Region, By
Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Alzheimer’s Disease Biomarkers Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Alzheimer’s Disease Biomarkers Market.
Contact
Mr. Ken Mathews
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com